Quantum BioPharma Featured in CTV Investigation Over Alleged Stock Manipulation
TL;DR
Quantum BioPharma's $700 million lawsuit against CIBC and RBC could expose stock manipulation tactics and potentially recover significant value for shareholders.
Quantum BioPharma alleges illegal stock spoofing tactics in its lawsuit while advancing Lucid-MS, a drug candidate shown to reverse nerve degradation in preclinical studies.
Quantum BioPharma's Lucid-MS drug candidate offers hope for multiple sclerosis patients by potentially halting and reversing nerve-cell degradation to improve quality of life.
CTV's W5 investigative series examines Quantum BioPharma's allegations of market manipulation while highlighting their promising MS drug that reverses nerve damage in animal studies.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that CTV News' flagship investigative program W5 is airing a three-part series examining the company and its allegations of stock market manipulation. The investigation focuses on what the company describes as illegal trading tactics that threatened its multiple sclerosis research program.
The W5 investigative report, led by reporter Jon Woodward, highlights "stock spoofing," an illegal trading tactic that forms the central allegation in Quantum BioPharma's $700 million lawsuit against CIBC and RBC. The company's CEO Zeeshan Saeed expressed gratitude for W5's reporting and reaffirmed the company's commitment to advancing Lucid-MS, its lead drug candidate for multiple sclerosis treatment.
According to the company's statement, Lucid-MS has shown promising results in animal studies, demonstrating potential to halt and reverse nerve-cell degradation associated with multiple sclerosis. The drug candidate represents a patented new chemical entity that Quantum BioPharma claims can prevent and reverse myelin degradation, which is the underlying mechanism of multiple sclerosis.
Quantum BioPharma maintains a diverse portfolio beyond its multiple sclerosis research. The company retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, and receives royalty payments of 7% of sales from the unbuzzd(TM) product until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also maintains strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
The CTV W5 investigation raises important questions about market manipulation practices in the biopharmaceutical sector and their potential impact on companies developing treatments for serious medical conditions. The full press release detailing the company's position is available at https://ibn.fm/5join. Additional company news and updates relating to QNTM are accessible in the company's newsroom at https://ibn.fm/QNTM.
This case highlights the vulnerability of emerging biotech companies to market manipulation tactics and the potential consequences for medical research advancement. The outcome of Quantum BioPharma's lawsuit and the findings from the W5 investigation could have significant implications for how financial institutions and regulators address alleged market manipulation practices affecting companies in the healthcare sector.
Curated from InvestorBrandNetwork (IBN)
